Arsenic hexoxide enhances TNF-α-induced anticancer effects by inhibiting NF-κB activity at a safe dose in MCF-7 human breast cancer cells

Kim,Min Jeong; Jung,Ji Hyun; Lee,Won Sup; Yun,Jeong Won; Lu,Jing  Nan; Yi,Sang  Mi; Kim,Hye  Jung; Chang,Seong-Hwan; Kim,Gon-Sup; Hong,Soon  Chan; Ha,Woo  Song

doi:10.3892/or.2014.3085

Arsenic hexoxide enhances TNF-α-induced anticancer effects by inhibiting NF-κB activity at a safe dose in MCF-7 human breast cancer cells

Authors:
- Min Jeong Kim
- Ji Hyun Jung
- Won Sup Lee
- Jeong Won Yun
- Jing Nan Lu
- Sang Mi Yi
- Hye Jung Kim
- Seong-Hwan Chang
- Gon-Sup Kim
- Soon Chan Hong
- Woo Song Ha
View Affiliations

Affiliations: Department of Internal Medicine, Institute of Health Sciences, Gyeongsang National University School of Medicine, Jinju 660-702, Republic of Korea, Department of Pharmacology, Institute of Health Sciences, Gyeongsang National University School of Medicine, Jinju 660-702, Republic of Korea, Department of Surgery, Konkuk University School of Medicine, Seoul 143-701, Republic of Korea, School of Veterinary Medicine and Research Institute of Life Science, Gyeongsang National University, Jinju 660-701, Republic of Korea, Department of Surgery, Institute of Health Sciences, Gyeongsang National University School of Medicine, Jinju 660-702, Republic of Korea
Published online on: March 12, 2014 https://doi.org/10.3892/or.2014.3085
Pages: 2305-2311

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Arsenic hexoxide (As4O6) has been used in Korean folk remedy for the treatment of cancer since the late 1980s. Evidence suggests that the anticancer effects of As4O6 are different from those of As2O3. Tumor necrosis factor-α (TNF-α) is generally increased in advanced cancer and is closely related to cancer progression, although it has cancer-killing effects. The reason is that TNF-α activates nuclear factor-κB (NF-κB) that is involved in cell proliferation, invasion, drug resistance and metastasis. In the present study, we investigated the effects of As4O6 on NF-κB activity, NF-κB-mediated cellular responses, and NF-κB-regulated gene expressions involved in metastasis at the concentrations of As4O6 where no cytotoxicity was observed. As4O6 suppressed NF-κB activation in both TNF-α-treated and control cells, and also suppressed IκB phosphorylation in a time-dependent manner, suggesting the suppression of NF-κB results, in part, from the inhibition of IκB degradation. We also confirmed the anti-NF-κB activity of As4O6 with synergism with TNF-α by augmenting caspase-8 activation. As4O6 also suppressed NF-κB activation induced by TNF-α, and some of the downstream NF-κB-regulated proteins involved in cancer proliferation, anti-apoptosis and metastasis. In conclusion, the present study demonstrated that As4O6 has anticancer properties by inhibiting NF-κB activation and NF-κB-regulated proteins at least in part through the inhibition of IκB phosphorylation, especially in the conditions of advanced cancer where TNF-α is highly secreted.

View Figures

View References

1	Kamangar F, Dores GM and Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 24:2137–2150. 2006. View Article : Google Scholar
2	Jung KW, Park S, Kong HJ, Won YJ, Lee JY, Seo HG, et al: Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2009. Cancer Res Treat. 44:11–24. 2012. View Article : Google Scholar : PubMed/NCBI
3	Nguyen DX and Massague J: Genetic determinants of cancer metastasis. Nat Rev Genet. 8:341–352. 2007. View Article : Google Scholar : PubMed/NCBI
4	Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, et al: Use of arsenic trioxide (As₂O₃) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 89:3354–3360. 1997.PubMed/NCBI
5	Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS, et al: Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood. 94:3315–3324. 1999.
6	Munshi NC, Tricot G, Desikan R, Badros A, Zangari M, Toor A, et al: Clinical activity of arsenic trioxide for the treatment of multiple myeloma. Leukemia. 16:1835–1837. 2002. View Article : Google Scholar : PubMed/NCBI
7	Lin YC, Li DR and Lin W: Relationship between radiotherapy enhancing effect of arsenic trioxide and the proliferation and apoptosis of related protein in nasopharyngeal carcinoma patients. Zhongguo Zhong Xi Yi Jie He Za Zhi. 27:704–707. 2007.(In Chinese).
8	Welch JS, Klco JM, Gao F, Procknow E, Uy GL, Stockerl-Goldstein KE, et al: Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a phase I study. Am J Hematol. 86:796–800. 2011. View Article : Google Scholar : PubMed/NCBI
9	Beer TM, Tangen CM, Nichols CR, Margolin KA, Dreicer R, Stephenson WT, et al: Southwest Oncology Group phase II study of arsenic trioxide in patients with refractory germ cell malignancies. Cancer. 106:2624–2629. 2006. View Article : Google Scholar : PubMed/NCBI
10	Chang HS, Bae SM, Kim YW, Kwak SY, Min HJ, Bae IJ, et al: Comparison of diarsenic oxide and tetraarsenic oxide on anticancer effects: Relation to the apoptosis molecular pathway. Int J Oncol. 30:1129–1135. 2007.PubMed/NCBI
11	Han MH, Lee WS, Lu JN, Yun JW, Kim G, Jung JM, et al: Tetraarsenic hexoxide induces Beclin-1-induced autophagic cell death as well as caspase-dependent apoptosis in U937 human leukemic cells. Evid Based Complement Alternat Med. 2012:2014142012.PubMed/NCBI
12	Messmer UK, Pereda-Fernandez C, Manderscheid M and Pfeilschifter J: Dexamethasone inhibits TNF-α-induced apoptosis and IAP protein downregulation in MCF-7 cells. Br J Pharmacol. 133:467–476. 2001.
13	Aggarwal BB: Nuclear factor-κB: the enemy within. Cancer Cell. 6:203–208. 2004.
14	Correia M, Cravo M, Marques-Vidal P, Grimble R, Dias-Pereira A, Faias S, et al: Serum concentrations of TNF-alpha as a surrogate marker for malnutrition and worse quality of life in patients with gastric cancer. Clin Nutr. 26:728–735. 2007. View Article : Google Scholar : PubMed/NCBI
15	Tas F, Duranyildiz D, Argon A, Oguz H, Camlica H, Yasasever V, et al: Serum levels of leptin and proinflammatory cytokines in advanced-stage non-small cell lung cancer. Med Oncol. 22:353–358. 2005. View Article : Google Scholar : PubMed/NCBI
16	Guttridge DC, Albanese C, Reuther JY, Pestell RG and Baldwin AS Jr: NF-κB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol. 19:5785–5799. 1999.
17	Cui ZG, Hong NY, Guan J, Kang HK, Lee DH, Lee YK, et al: cAMP antagonizes ERK-dependent antiapoptotic action of insulin. BMB Rep. 44:205–210. 2011. View Article : Google Scholar : PubMed/NCBI
18	Wajant H, Pfizenmaier K and Scheurich P: Tumor necrosis factor signaling. Cell Death Differ. 10:45–65. 2003. View Article : Google Scholar : PubMed/NCBI
19	Chen G and Goeddel DV: TNF-R1 signaling: a beautiful pathway. Science. 296:1634–1635. 2002. View Article : Google Scholar : PubMed/NCBI
20	Gaur U and Aggarwal BB: Regulation of proliferation, survival and apoptosis by members of the TNF superfamily. Biochem Pharmacol. 66:1403–1408. 2003. View Article : Google Scholar : PubMed/NCBI
21	Demchenko YN and Kuehl WM: A critical role for the NFκB pathway in multiple myeloma. Oncotarget. 1:59–68. 2010.
22	Kerbauy DM, Lesnikov V, Abbasi N, Seal S, Scott B and Deeg HJ: NF-κB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs). Blood. 106:3917–3925. 2005.
23	Han SS, Kim K, Hahm ER, Park CH, Kimler BF, Lee SJ, et al: Arsenic trioxide represses constitutive activation of NF-κB and COX-2 expression in human acute myeloid leukemia, HL-60. J Cell Biochem. 94:695–707. 2005.
24	Jamnitski A, Levels JH, Oever IA and Nurmohamed MT: High-density lipoprotein profiling changes in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a cohort study. J Rheumatol. 40:825–830. 2013. View Article : Google Scholar
25	Davies B, Waxman J, Wasan H, Abel P, Williams G, Krausz T, et al: Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res. 53:5365–5369. 1993.PubMed/NCBI
26	Bogenrieder T and Herlyn M: Axis of evil: molecular mechanisms of cancer metastasis. Oncogene. 22:6524–6536. 2003. View Article : Google Scholar : PubMed/NCBI
27	Vihinen P and Kahari VM: Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer. 99:157–166. 2002. View Article : Google Scholar : PubMed/NCBI
28	Gilmore TD: Introduction to NF-κB: players, pathways, perspectives. Oncogene. 25:6680–6684. 2006.
29	Chun KS and Surh YJ: Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention. Biochem Pharmacol. 68:1089–1100. 2004. View Article : Google Scholar : PubMed/NCBI
30	Schmidt EV: The role of c-myc in regulation of translation initiation. Oncogene. 23:3217–3221. 2004.
31	Chen ZJ, Parent L and Maniatis T: Site-specific phosphorylation of IκBα by a novel ubiquitination-dependent protein kinase activity. Cell. 84:853–862. 1996.